Session

Gastric and oesophageal preneoplastic lesions: Diagnosis and treatment

SIMPLE CYTOSPONGE-BIOMARKER TECHNOLOGY TO PRIORITIZE ENDOSCOPIC BARRETT’S ESOPHAGUS SURVEILLANCE
SIMPLE CYTOSPONGE-BIOMARKER TECHNOLOGY TO PRIORITIZE ENDOSCOPIC BARRETT’S ESOPHAGUS SURVEILLANCE

UTILISATION OF THE CYTOSPONGE DEVICE AS A TOOL FOR RISK STRATIFICATION IN PATIENTS WITH BARRETT’S OESOPHAGUS WHO ARE OVERDUE ENDOSCOPIC SURVEILLANCE DUE TO THE COVID-19 PANDEMIC
UTILISATION OF THE CYTOSPONGE DEVICE AS A TOOL FOR RISK STRATIFICATION IN PATIENTS WITH BARRETT’S OESOPHAGUS WHO ARE OVERDUE ENDOSCOPIC SURVEILLANCE DUE TO THE COVID-19 PANDEMIC

CYTOSPONGE-TFF3 TESTING CAN DETECT PRE-CANCEROUS MUCOSAL CHANGES OF THE STOMACH
CYTOSPONGE-TFF3 TESTING CAN DETECT PRE-CANCEROUS MUCOSAL CHANGES OF THE STOMACH

ENDOSCOPIC SUBMUCOSAL DISSECTION AS FIRST LINE THERAPY FOR NEOPLASTIC BARRETT’S ESOPHAGUS WITH VISIBLE LESIONS
ENDOSCOPIC SUBMUCOSAL DISSECTION AS FIRST LINE THERAPY FOR NEOPLASTIC BARRETT’S ESOPHAGUS WITH VISIBLE LESIONS

NEAR-INFRARED FLUORESCENCE MOLECULAR ENDOSCOPY SHOWS PROMISING RESULTS IN DETECTING DYSPLASTIC ESOPHAGEAL LESIONS USING TOPICALLY ADMINISTERED BEVACIZUMAB-800CW: THE PRELIMINARY RESULTS OF A PHASE 2 STUDY
NEAR-INFRARED FLUORESCENCE MOLECULAR ENDOSCOPY SHOWS PROMISING RESULTS IN DETECTING DYSPLASTIC ESOPHAGEAL LESIONS USING TOPICALLY ADMINISTERED BEVACIZUMAB-800CW: THE PRELIMINARY RESULTS OF A PHASE 2 STUDY

NEAR-INFRARED FLUORESCENCE MOLECULAR ENDOSCOPY SHOWS PROMISING RESULTS IN DETECTING DYSPLASTIC ESOPHAGEAL LESIONS USING TOPICALLY ADMINISTERED BEVACIZUMAB-800CW: THE PRELIMINARY RESULTS OF A PHASE 2 STUDY
NEAR-INFRARED FLUORESCENCE MOLECULAR ENDOSCOPY SHOWS PROMISING RESULTS IN DETECTING DYSPLASTIC ESOPHAGEAL LESIONS USING TOPICALLY ADMINISTERED BEVACIZUMAB-800CW: THE PRELIMINARY RESULTS OF A PHASE 2 STUDY

Gastric and oesophageal preneoplastic lesions: Diagnosis and treatment  et al.

ENDOSCOPIC SUBMUCOSAL DISSECTION AS FIRST LINE THERAPY FOR NEOPLASTIC BARRETT’S ESOPHAGUS WITH VISIBLE LESIONS
ENDOSCOPIC SUBMUCOSAL DISSECTION AS FIRST LINE THERAPY FOR NEOPLASTIC BARRETT’S ESOPHAGUS WITH VISIBLE LESIONS

Gastric and oesophageal preneoplastic lesions: Diagnosis and treatment  et al.

CYTOSPONGE-TFF3 TESTING CAN DETECT PRE-CANCEROUS MUCOSAL CHANGES OF THE STOMACH
CYTOSPONGE-TFF3 TESTING CAN DETECT PRE-CANCEROUS MUCOSAL CHANGES OF THE STOMACH

Gastric and oesophageal preneoplastic lesions: Diagnosis and treatment  et al.

UTILISATION OF THE CYTOSPONGE DEVICE AS A TOOL FOR RISK STRATIFICATION IN PATIENTS WITH BARRETT’S OESOPHAGUS WHO ARE OVERDUE ENDOSCOPIC SURVEILLANCE DUE TO THE COVID-19 PANDEMIC
UTILISATION OF THE CYTOSPONGE DEVICE AS A TOOL FOR RISK STRATIFICATION IN PATIENTS WITH BARRETT’S OESOPHAGUS WHO ARE OVERDUE ENDOSCOPIC SURVEILLANCE DUE TO THE COVID-19 PANDEMIC

Gastric and oesophageal preneoplastic lesions: Diagnosis and treatment  et al.

SIMPLE CYTOSPONGE-BIOMARKER TECHNOLOGY TO PRIORITIZE ENDOSCOPIC BARRETT’S ESOPHAGUS SURVEILLANCE
SIMPLE CYTOSPONGE-BIOMARKER TECHNOLOGY TO PRIORITIZE ENDOSCOPIC BARRETT’S ESOPHAGUS SURVEILLANCE

Gastric and oesophageal preneoplastic lesions: Diagnosis and treatment  et al.

Item 1 - 10 / 10
1